Objective-P2Y 12 is a well-recognized receptor expressed on platelets and the target of thienopyridine-type antiplatelet drugs. However, recent evidence suggests that P2Y 12 expressed in vessel wall plays a role in atherogenesis, but the mechanisms remain elusive. In this study, we examined the molecular mechanisms of how vessel wall P2Y 12 mediates vascular smooth muscle cells (VSMCs) migration and promotes the progression of atherosclerosis. Approach and Results-Using a high-fat diet-fed apolipoprotein E-deficient mice model, we found that the expression of P2Y 12 in VSMCs increased in a time-dependent manner and had a linear relationship with the plaque area. Moreover, administration of P2Y 12 receptor antagonist for 12 weeks caused significant reduction in atheroma and decreased the abundance of VSMCs in plaque. In cultured VSMCs, we found that activation of P2Y 12 receptor inhibited cAMP/ protein kinase A signaling pathway, which induced cofilin dephosphorylation and filamentous actin disassembly, thereby enhancing VSMCs motility and migration. In addition, the number of P2Y 12 -positive VSMCs was decreased in the carotid artery plaque from patients receiving clopidogrel. Conclusions-Vessel wall P2Y 12 receptor, which promotes VSMCs migration through cofilin dephosphorylation, plays a critical role in the development of atherosclerotic lesion and may be used as a therapeutic target for atherosclerosis. Visual Overview-An online visual overview is available for this article. 
A therosclerosis, a disease of large arteries, is the foremost cause of stroke and heart disease and the leading causes of death and disability worldwide. 1 Atherosclerotic lesion formation involves a series of cellular and molecular changes, and the pathological mechanisms underlying the onset and progression of atherosclerosis remain elusive.
2 P2Y 12 receptor antagonists, such as clopidogrel, prasugrel, and ticagrelor, are well-established antithrombotic drugs. 3 Although emerging clinical and experimental studies have indicated that they may exert an antiatherosclerosis effect besides the antithrombotic effect, but there are also some studies which showed negative results. 4 P2Y 12 receptor is a member of the P2 receptor family, which consists of the ion-channel P2X and the G-proteincoupled P2Y receptors. P2 receptors are activated by adenine nucleotides, adenosine triphosphate or adenosine diphosphate (ADP), which are released from platelets, endothelial cells, and immune cells. 5 P2Y 12 was originally identified in platelets. After stimulation by ADP, P2Y 12 inhibits adenylyl cyclase and plays a central role in platelet activation and thrombosis. Thereby clinically, P2Y 12 receptor has been used as a target for the treatment of thromboembolism.
6,7 P2Y 12 was also found expressed in vascular smooth muscle cells (VSMCs) and mediates vessel contractile function. 8 A recent study has suggested that P2Y 12 is critical for atherosclerotic plaque development in hypercholesterolemic low-density lipoprotein receptor-deficient mice because of its contribution to platelet-leukocyte aggregate formation and leukocyte recruitment to the lesion area. 9 In addition, another study on apolipoprotein E null (ApoE −/− ) and double-knockout ApoE −/− P2Y 12 −/− mice has also demonstrated that P2Y 12 deficiency moderates the procession of atherosclerosis. However, vessel wall P2Y 12 receptor, but not platelet P2Y 12 receptor, potentiates early atherogenesis. 4 Interestingly, P2Y 12 was overexpressed in smooth muscle cells (SMCs) of human carotid plaques, and P2Y 12 -positive VSMCs were distributed in the vicinity of the necrotic core. 10 This evidence suggests that VSMCs P2Y 12 is associated with atherogenesis. But by far, the underlying mechanisms remain to be elucidated.
VSMCs is the main cell type in vessel wall and a major component of most stages of human atherosclerosis. 11 It is well recognized that the migration of VSMCs from the media to the intima plays an important role during the progression of atherosclerosis.
On the basis of these studies, we proposed that P2Y 12 promotes the progression of atherosclerosis through enhancing March 2017
VSMCs migration. In this study, we firstly investigated whether P2Y 12 inhibitor could influence the progression of atherosclerosis in vivo, and then we examined the molecular mechanisms underlying P2Y 12 -mediated VSMCs migration.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

P2Y 12 Receptor Antagonist Attenuates Atherosclerosis in ApoE −/− Mice
To investigate the effect of P2Y 12 receptor on atherogenesis, ApoE −/− mice were fed with high-fat diet (HFD) to induce atherogenesis. The mice were treated either with clopidogrel, which is a commonly used P2Y 12 receptor antagonist, or mannitol (vehicle) in addition to HFD for 4 or 12 weeks. Oil Red O staining showed that 4 weeks of clopidogrel treatment did not influence lesion size at either whole aorta or aortic arch when compared with vehicle. However, 12 weeks of clopidogrel treatment significantly reduced lesion area at whole aorta (12.53±1.22% versus control 20.19±1.79%; P<0.05) and aortic arch (23.07±3.10% versus control 33.05±2.18%; P<0.05; Figure 1A ). Oil Red O staining at aortic root showed similar results, that compared with control vehicle, clopidogrel administration for 12 weeks significantly decreased plaque lesion, whereas clopidogrel administration for 4 weeks had no effect on plaque size ( Figure 1B ). Hematoxylin and eosin staining of aortic roots also showed that clopidogrel administration for 12 weeks, but not for 4 weeks, reduced plaque area compared with vehicle administration ( Figure 1C (Figure 2A, upper) . Immunofluorescent staining of aortic roots sections showed that P2Y 12 was not expressed in the intima of normal diet-fed C57BL/6J mice and chow diet-fed ApoE −/− mice. While in the plaques of HFD-fed mice, we observed significant P2Y 12 expression in α-smooth muscle actin-positive cells. Further, the number of P2Y 12 positive VSMCs and the percentage of P2Y 12 -positive VSMCs in total VSMCs of plaque increased in a time-dependent manner ( Figure 2A , middle and bottom, 2B, and 2C). Moreover, a linear regression analysis revealed that the plaque area is positively related to the number of P2Y 12 -positive SMCs in plaque (y=0.0119x+0.095; R 2 =0.6318; P<0.001; Figure 2D ). To further support our finding that P2Y 12 was expressed by VSMCs during atherogenesis in vitro, we treated cultured mice aortic SMCs with oxidized low-density lipoprotein (OxLDL), which is an important proatherogenic factor. Both Western blots and quantitative real-time reverse transcription-polymerase chain reaction analysis showed that OxLDL stimulated P2Y 12 expression in VSMCs ( Figure 2E and 2F). We next examined the mechanisms of OxLDL-induced P2Y 12 expression in SMCs. Because nuclear factor κB (NF-κB) has been proved to transcriptionally upregulate P2Y 12 expression, 10 and OxLDL was reported to stimulate NF-κB activation in VSMCs, 12 we postulated that OxLDL may regulate P2Y 12 expression via activation of NF-κB. To test this hypothesis, we treated cultured VSMCs with OxLDL in the presence or absence of NF-κB inhibitor BAY 11-7021. After 3.5 hours of OxLDL (50 μg/mL) stimulation, the phosphorylation of NF-κB-binding protein IκBα (inhibitor of NF-κB, alpha) was significantly increased, and NF-κB was induced to translocate into the nucleus ( Figure IA and IB in the online-only Data Supplement). Furthermore, when SMCs were pre-treated with BAY 11-7082 (10 μmol/L) for 2 hours before incubation with OxLDL, OxLDL-induced P2Y 12 upregulation was abolished ( Figure IC in the online-only Data Supplement). Therefore, we may infer that OxLDL activates NF-κB and induces NF-κB translocation into the nucleus and promotes P2Y 12 expression.
P2Y 12 Promotes Migration and Filamentous Actin Disassembly in VSMCs
Because P2Y 12 expression in SMCs is associated with the progression of atherosclerosis, we further explored the role of VSMCs P2Y 12 in atherogenesis. VSMCs migrate from the media to the intima and play an important role in the progression of atherosclerosis. To determine whether P2Y 12 Figure 3A) . To preclude the effect of cell proliferation in transwell experiments, we examined whether 6 hours of P2Y 12 agonist stimulation influenced VSMCs proliferation using Ki67 immunofluorescent staining. The results showed that ADP or P2Y 12 receptor inhibitor 2-MeSAMP had no significant effect on VSMCs proliferation within 6 hours, indicating activation of P2Y 12 increased cell migration, but not proliferation in our transwell experiments ( Figure IIA in the online-only Data Supplement). We further performed wound-healing scratch experiments to validate our results. We used mitomycin C to block cell proliferation and found that after 48 hours of stimulation, ADPβs (adenosine 5′-[β-thio]diphosphate; a nonhydrolyzable ADP analog; 10 μmol/L) promoted wound healing by ≈20.93%, whereas 2-MeSAMP alone inhibited wound healing by ≈7.75% when compared with control cells. What is more, 2-MeSAMP significantly inhibited ADPβs-induced wound healing ( Figure 3B) . These results also demonstrate that P2Y 12 mediates VSMCs migration in vitro.
Cell migration is partly controlled by cytoskeleton reorganization. 13 To determine whether VSMCs P2Y 12 receptor mediates dynamic rearrangement of actin, filamentous actin (F-actin) of VSMCs was visualized by fluorescent phalloidin staining. After cells were stimulated with ADP for 30 minutes, we observed substantial F-actin disassembly in the activated cells, whereas no significant F-actin disassembly was observed in the untreated control cells and in 2-MeSAMP-stimulated cells. When 2-MeSAMP was added in the presence of ADP, it partly abolished F-actin disassembly induced by ADP ( Figure 3C ).
To quantify F-actin disassembly mediated by P2Y 12 , we determined the content of global actin (G-actin) and F-actin in VSMCs after agonists incubation for 30 minutes. Immunoblots of actin contents in supernatant (G-actin) and pellet (F-actin) showed that compared with control cells, ADP stimulation increased the proportion of G-actin to F-actin in VSMCs by ≈3.37-fold, whereas 2-MeSAMP abolished this effect in the presence of ADP. Moreover, 2-MeSAMP alone had no significant influence on the content of G-actin to F-actin ( Figure 3D ). These results indicate that P2Y 12 receptor is responsible for ADP-induced migration and F-actin disassembly of VSMCs. To further confirm our findings, we downregulated P2Y 12 expression in mice VSMCs via lentivirus-mediated P2Y 12 specific short hairpin RNA (shRNA). Compared with control empty vector-transduced cells, P2Y 12 shRNA-transduced cells expressed much less P2Y 12 protein ( Figure 3E , upper). In control cells, compared with unstimulated group, ADP or ADPβs induced significant cell migration and wound healing. Meanwhile, depletion of P2Y 12 abolished the effect of ADP or ADPβs on cell migration and wound healing ( Figure 3E , bottom; Figure 3F ). P2Y 12 shRNA also attenuated the increased ratio of G-actin:F-actin by ADP ( Figure 3G ).
P2Y 12 Mediates Cofilin Activation to Promote VSMCs F-Actin Disassembly and Migration
We next investigated the molecular mechanisms underlying actin filaments disassembly induced by P2Y 12 . Actin-depolymerizing factor/cofilin family and myosin light chain are key actin-binding proteins that involved in actin depolymerizing.
14 Their activities are regulated by phosphorylation (inactive form) and dephosphorylation (active form). 15 Therefore, phosphorylation of cofilin and myosin light chain in VSMCs was examined. Western blots showed that compared with unstimulated control VSMCs, ADP (10 μmol/L) treatment for 20 minutes caused significant dephosphorylation of cofilin, and this effect was significantly attenuated by 2-MeSAMP (100 μmol/L). 2-MeSAMP alone slightly increased cofilin phosphorylation. Total cofilin protein remained stable during the incubation. Myosin light chain phosphorylation and total myosin light chain was not influenced by ADP or 2-MeSAMP in VSMCs ( Figure 4A ). In VSMCs transfected with control shRNA, ADP also induced significant cofilin dephosphorylation (to 0.22 of unstimulated control). While in VSMCs transfected with P2Y 12 shRNA, ADP-induced cofilin dephosphorylation was significantly decreased (to 0.74 of unstimulated control) as compared to VSMCs transfected with control shRNA ( Figure 4B ).
To determine whether cofilin activity contributes to ADPinduced F-actin disassembly and cell migration, we generated 2 myc-tagged cofilin variants, wide-type cofilin and S3E cofilin (constitutively phosphorylated and inactive) as previously described. 16 Immunoblots determined significant overexpression of myc-cofilin in cells transfected with wide-type cofilin or S3E cofilin when compared with cells transfected with vector control ( Figure 4C ). In control and wide-type cofilin-expressing cells, ADP induced significant F-actin disassembly and thereby increased the ratio of G-actin:F-actin, whereas in S3E cofilin-expressing cells, ADP induced F-actin disassembly, and the increased proportion of G-actin to F-actin was abolished ( Figure 4D through 4E ). In addition, in control and wide-type cofilin-expressing cells, ADP stimulation increased VSMCs migration by 68% and 77.9%, respectively. On the contrary, overexpression of cofilin S3E abolished cell migration induced by ADP ( Figure 4F ). All these results indicate that activation (dephosphorylation) of cofilin is required for P2Y 12 -mediated F-actin disassembly and cell migration.
P2Y 12 Inhibits cAMP/Protein Kinase A Signaling Pathway, Causing Cofilin Dephosphorylate in VSMCs
We further investigated the potential signaling pathways underlying P2Y 12 -induced cofilin dephosphorylation. It is well recognized that activation of P2Y 12 receptor inhibits adenylyl cyclase in platelets and thereby inhibits the activity of cAMP/protein kinase A (PKA) signaling pathway. 17 We examined whether similar mechanisms are responsible for cofilin dephosphorylation in VSMCs. cAMP enzyme-linked immunosorbent assay showed that compared with unstimulated VSMCs, ADP (10 μmol/L) induced significant decrease in cAMP level (to 0.28 of control). On the contrary, 2-MeSAMP (100 μmol/L) increased cAMP level (by 2.93-fold of control). Furthermore, 2-MeSAMP abolished the decreasing effect of ADP on cAMP level. Determination of PKA activity in VSMCs showed similar change as cAMP level. Compared with unstimulated VSMCs, ADP alone decreased PKA activity (to 0.73 of control) in VSMCs, and this effect was inhibited in the presence of 2-MeSAMP. In addition, 2-MeSAMP alone slightly increased PKA activity (by 0.32 of control). These results demonstrate that ADP could inhibit cAMP/PKA activity through P2Y 12 receptor ( Figure 5A and 5B).
To examine whether PKA activity mediates cofilin phosphorylation and cell migration, we treated VSMCs with either H-89 (40 μmol/L), an inhibitor of PKA activity (protein kinase inhibitor) or sp-Adenosine 3′,5′-cyclic monophosphorothioate triethylammonium salt (sp-cAMP; 100 μmol/L), an active cell-permeable cAMP analog, or rolipram, an inhibitor of phosphodiesterase 4 (SMCs specific). We found that compared with control cells, sp-cAMP and rolipram both increased cofilin phosphorylation when added alone. What is more, sp-cAMP and rolipram inhibited ADP-induced cofilin dephosphorylation ( Figure 5C ; Figure IVA in the online-only VSMCs expressing myc-tagged widetype (WT) cofilin or inactive (constitutively phosphorylated) S3E cofilin were generated and stimulated with ADP (10 μmol/L). C, Expression of p-cofilin, cofilin, and myc were determined by Western blots. D, F-actin (green) was costained with myc (red) and nucleus (blue). Scale bar, 10 μm. E, F-actin and global actin (G-actin) fractions were prepared and subjected to Western blots analysis, and the ratio of G-actin:F-actin was calculated. Figure 5C ). We next examined whether PKA activity mediates VSMCs migration. The result showed that when compared with control cells, sp-cAMP alone inhibited VSMCs migration, whereas protein kinase inhibitor increased VSMCs migration. In addition, sp-cAMP reversed ADPinduced VSMCs migration, whereas protein kinase inhibitor enhanced ADP-induced VSMCs migration ( Figure 5D ). All these results suggest that cAMP/PKA signaling pathway is the downstream of P2Y 12 , which participates in P2Y 12 -mediated cofilin dephosphorylation and VSMCs migration.
P2Y 12 Inhibitor Decreases VSMCs Migration in Both ApoE Null Mice and Patients
To testify the P2Y 12 -cAMP/PKA signaling pathway in vivo, we determined cAMP level and PKA activity in the homogenates of aorta, which were obtained from normal diet-fed C57BL/6J mice and HFD-fed ApoE −/− mice. We found that, in vehicle-administrated ApoE −/− mice, the cAMP level, PKA activity, and phosphorylated cofilin were decreased to 0.21, 0.34, and 0.22 of control normal diet-fed mice, respectively. While clopidogrel administration significantly increased cAMP level, PKA activity, and cofilin phosphorylation in aorta of HFD-fed ApoE −/− mice when compared with vehicle administration ( Figure 6A through 6C) .
To determine whether P2Y 12 inhibition attenuates the progression of atherosclerosis by reducing VSMCs migration from the media to the intima, we analyzed the number of VSMCs in plaque. Immunofluorescence showed that HFDfed mice developed significant plaque, whereas chow diet-fed control mice did not develop intimal hyperplasia or plaque. Many VSMCs in the plaque were P2Y 12 positive. Clopidogrel treatment significantly reduced the number of P2Y 12 -positive VSMCs in the plaque ( Figure 6D) .
We further extended our study to human carotid artery plaques from patients undergoing carotid endarterectomy. Five male patients (aged between 40 and 80 years) were enrolled to each group. They had symptomatic or asymptomatic internal carotid artery stenosis ≥70% as detected by duplex sonography and confirmed using computed tomographic angiography. The control patients only received aspirin (100 mg/d) before surgery, whereas the clopidogrel group received both clopidogrel (75 mg/d) and aspirin (100 mg/d) before surgery (Table I in the online-only Data Supplement). Immunofluorescent staining showed that most of the SMCs in those plaques were P2Y 12 positive. Interestingly, the density of P2Y 12 -positive SMCs was significantly decreased in plaques from patients who took clopidogrel compared with those from patients who did not take any P2Y 12 antagonists ( Figure 6E ). These results suggest that blockade of P2Y 12 may ameliorate VSMCs migration and plaque progression in patients.
Discussion
The major findings of this study were that (1) P2Y 12 antagonist caused significant reduction in atheroma and decreased the abundance of VSMCs in plaque, (2) the expression of P2Y 12 in VSMCs within plaque increased in a time-dependent manner during atherogenesis and had a linear relationship with the plaque area, (3) activation of P2Y 12 receptor induced cofilin dephosphorylation through inhibition of cAMP/PKA signaling pathway, which depolymerized F-actin and promoted cytoskeleton turnover, thereby enhancing the migration of VSMCs. To the best of our knowledge, our study demonstrated that P2Y 12 antagonist, besides the antithrombotic effect, has an antiatherosclerotic effect for long-time but not short-time treatment, and we have also provided the molecular mechanisms of how vessel wall P2Y 12 receptor promoted VSMCs migration and atherogenesis.
Mammalian P2Y 12 receptor was first found to be expressed on platelets and is responsible for amplifying and sustaining platelet activation, which results in platelet aggregation and coagulation. 7 However, recent studies suggest that P2Y 12 also plays a role in the pathogenesis of atherosclerosis. 18 Using ApoE −/− P2Y 12 −/− mice, Li et al 18 tested the effect of P2Y 12 on the development of atherosclerotic lesions. They found that P2Y 12 deficiency diminished plaque lesion area, increased fibrous content at the plaque site, and decreased monocyte/ macrophage infiltration of the lesions. They suggested that platelet P2Y 12 receptor modulates atherogenesis by augmenting inflammatory cell recruitment via regulation of platelet factor 4 release. 18 Nevertheless, another research reported that vessel wall P2Y 12 deficiency but not platelet P2Y 12 deficiency significantly attenuated atheroma in the aortic sinus and brachiocephalic artery, indicating an effect of vessel wall P2Y 12 . 4 In addition, Rauch et al 10 have found that P2Y 12 is expressed by VSMCs within atherosclerotic lesions, and thrombin transcriptionally upregulates P2Y 12 receptors in (human) VSMCs and that these P2Y 12 receptors mediate ADP-induced signaling, including VSMCs mitogenesis. However, the exact mechanisms underlying the role of VSMCs P2Y 12 in atherosclerosis remain largely unknown. In this study, we provide evidence that P2Y 12 receptor, when stimulated by its natural agonist ADP, induces VSMCs migration and may thereby enhancing VSMCs migration from media to intima and promoting the progression of atherogenesis.
In vitro, our study revealed that, OxLDL, which is of great importance in atherogenic process and has been found in atherosclerotic lesions, 19 increased the expression of P2Y 12 receptor at both mRNA and protein levels in VSMCs. These results are consistent with the previous studies that atherosclerosis-related factors such as nicotine and thrombin upregulate P2Y 12 receptor expression in VSMCs. 20 Similar to thrombininduced P2Y 12 expression, we provided evidence that OxLDL also induces P2Y 12 expression via activation of NF-κB.
In vivo, the increased expression of P2Y 12 receptor by VSMCs near the core of plaque exhibited a time-dependent pattern and had a linear correlation with plaque size, suggesting a role of vessel wall P2Y 12 in the progression of atherosclerosis. Several studies have demonstrated that P2Y 12 receptor antagonists have an antiatherogenic effect independent of antithrombotic function. 21 Interestingly, the effect of clopidogrel and the genotype which influences clopidogrel metabolism on the end point events or atherogenesis was time dependent. 4, 22 Similar with the previous observations, 4 we also found that in ApoE −/− mice, there was no difference in plaque size between clopidogrel-treated group and vehicletreated group at the fourth week. However, after a daily clopidogrel administration (20 mg/kg) for 12 weeks, plaque size in clopidogrel-treated group was substantially reduced when compared with vehicle-treated group. The time-dependent effect of clopidogrel on atherogenesis may be because of the fact that P2Y 12 expression in advanced plaque is higher than in early plaque. Thereby, it is possible that higher expression of P2Y 12 may lead to a more profound antiatherogenic effect of clopidogrel. The distribution of P2Y 12 in plaque mainly occurred in VSMCs and hardly occurred in macrophages. 23 At the fourth week, we only observed a little increase of the absolute number of VSMCs in the plaque. This is consistent with the previous findings that early lesions of atherosclerosis mainly consist of the accumulation of macrophage-derived foam cells. While the migration of VSMCs from media to intima happens at a latter stage of atherosclerosis. 24 During the progression of atherosclerosis, the migration and proliferation of VSMCs both play a role. The study of Rauch et al 10 indicated a role of P2Y 12 in VSMCs cell proliferation. In this study, we treated mouse VSMCs with ADP or ADPβs or (and) 2-MeSAMP for 6 or 72 hours and then performed Ki67 (a molecular marker of cell proliferation) immunofluorescent staining. The results showed that direct activation of P2Y 12 for 72 hours mediates VSMCs proliferation ( Figure IIA in the online-only Data Supplement). As by far, there is no direct biological marker to trace the migration of VSMCs in vivo, we cannot decide whether certain VSMCs in plaque were migration originated or proliferation originated. Nevertheless, we provided substantial evidence which indicates that P2Y 12 may contribute to the progression of atherosclerosis at least in part by enhancing VSMCs migration from media to intima. Of note, in the study of Rauch et al, 10 direct stimulation of P2Y 12 receptor by its agonist 2-MeSADP did not increase human VSMCs proliferation. DNA synthesis was significantly enhanced only when 2-MeSADP was added after preincubation of cells with thrombin for 6 hours. The difference between their study and ours may be explained by the reason that the abundance of P2Y 12 is much less in human VSMCs than in mouse VSMCs under normal condition (data not shown). Because pre-incubation of human VSMCs with thrombin upregulates P2Y 12 expression, 10 it is easy to understand that P2Y 12 activation augmented thrombin-induced VSMCs proliferation in their study. In vivo, we also provided evidence that clopidogrel inhibited VSMCs proliferation ( Figure IIB in the online-only Data Supplement). Therefore, clopidogrel may directly inhibit atherogenesis via antimigratory and antimitogenesis effects on VSMCs.
On the other hand, we cannot either preclude the possibility of platelet P2Y 12 involving in clopidogrel-mediated atherogenesis. Atherosclerosis has been viewed as a chronic inflammatory process of vessel wall. 25 Platelet P2Y 12 is responsible for sustaining of platelet activation, leading to the release of platelet factor 4 and activation of adhesion molecules, such as P-selectin and integrin, which can contribute to inflammatory cell recruitment. 9, 18 Therefore, platelet inhibition may influence the progression of atherosclerosis. It has been reported that clopidogrel reduces CD4 + , CD8 + T cells, and macrophages infiltration in plaque, and the reason may be because of reduced adhesion molecules level such as intercellular adhesion molecule-1, E-selectin/P-selectin and cytokine level such as membrane cofactor protein-1 and platelet-derived growth factor. 26 In addition, cytokines such as platelet-derived growth factor and transforming growth factor-β released by activated platelet have been demonstrated to enhance VSMCs migration or proliferation in vitro. 27, 28 Thus, platelet inhibition may indirectly inhibit VSMCs migration or proliferation during atherogenesis.
VSMCs play a critical role in the progression of atherosclerosis. 11 During the development of atherosclerotic plaque, VSMCs migrate from the media to the intima and form a neointima, nucleating the development of an organized atherosclerotic plaque. A variety of growth factors and cytokines could regulate the migration of VSMCs. 11 We found that ADP treatment promotes VSMCs migration, and this effect was abolished by P2Y 12 inhibitor 2-MeSAMP, indicating that activation of P2Y 12 is required for ADP-induced migration of VSMCs. The migration of VSMCs involves changes at 2 aspects, one hand is cytoskeleton and the other hand is extracellular matrix. 29 In this study, we provide evidence that ADP activates P2Y 12 receptor and induces cytoskeleton turnover through cofilin dephosphorylation, which enhances the migration of VSMCs. The mammalian actin-depolymerizing factor/cofilin promotes cytoskeletal dynamics by depolymerizing actin filaments. This activity is critical for several processes, such as cytokinesis, cell motility, and differentiation. 30 Consistent with our findings, the activation of P2Y receptors by nucleotides has been shown to induce reorganization of the actin cytoskeleton in VSMCs. 31 In accordance with the regulatory role of cofilin in the cytoskeletal dynamics, overexpression of pseudophosphorylated form (S3E cofilin) abolished the promigratory effect of ADP. Moreover, a previous study on Chinese hamster ovary cells demonstrated that P2Y 12 receptor activation is responsible for actin cytoskeleton organization through Rho-kinase-dependent pathway. 32 However, interaction of these pathways during the regulation of VSMCs migration needs to be further studied.
Similar to previous findings in platelet, 33 our study provided evidence that P2Y 12 , a Gi-coupled receptor, inhibits cAMP/ PKA signaling pathway in VSMCs under the stimulation of ADP. When P2Y 12 receptor is activated by ADP, the intracellular level of cAMP was decreased, and PKA activity was lowered. PKA enhances the phosphorylation of cofilin and is crucial in cell morphology and migration. 34 Inhibition of PKA by ADP thereby disturbs the balance between phosphorylated and dephosphorylated forms of cofilin. Dephosphorylated cofilin depolymerizes actin filaments, thereby providing a pool of actin monomers for filament assembly. P2Y 12 enhances VSMCs motility through regulating this dynamic reorganization of actin cytoskeleton.
In conclusion, our study demonstrates that P2Y 12 receptor enhances the migration of VSMCs via cofilin dephosphorylation and may play a role in atherogenesis, and P2Y 12 antagonist has a profound antiatherogenic effect for advanced plaque.
